Prot# BP39529: A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants with Early Parkinson's Disease with a 52 Week Blinded Extension (Pasadena)

Project: Research project

Project Details

Effective start/end date5/2/175/2/24


  • INC Research, LLC (Prot# BP39529 // Prot# BP39529)
  • Roche TCRC, Inc. (Prot# BP39529 // Prot# BP39529)